Editor's choice

Primary mucinous ovarian cancer: options for surgery and chemotherapy
Katherine C Kurnit, Michael Frumovitz

International Journal of Gynecologic Cancer Nov 2022, 32 (11) 1455-1462; DOI: 10.1136/ijgc-2022-003806
Adjuvant treatment after radical surgery for cervical cancer with intermediate risk factors: is it time for an update?
Juliana Rodriguez, David Viveros-Carreño, Rene Pareja

International Journal of Gynecologic Cancer Oct 2022, 32 (10) 1219-1226; DOI: 10.1136/ijgc-2022-003735
Incidence of lymph node metastasis in early-stage low-grade serous ovarian cancer: a systematic review
David Viveros-Carreño, Juliana Rodriguez, Rene Pareja

International Journal of Gynecologic Cancer Oct 2022, 32 (10) 1283-1288; DOI: 10.1136/ijgc-2022-003618
CERVANTES: an international randomized trial of radical surgery followed by adjuvant (chemo) radiation versus no further treatment in patients with early-stage, intermediate-risk cervical cancer (CEEGOG-CX-05; ENGOT-CX16)
David Cibula, Martina Borčinová, Roman Kocian, David Feltl, Sona Argalacsova, Pavel Dvorak, Daniela Fischerová, Pavel Dundr, Jiri Jarkovsky, Eva Höschlová, Jiri Slama, Giovanni Scambia

International Journal of Gynecologic Cancer Oct 2022, 32 (10) 1327-1331; DOI: 10.1136/ijgc-2022-003918
Endometrial stripe thickness: a preoperative marker to identify patients with endometrial intraepithelial neoplasia who may benefit from sentinel lymph node mapping and biopsy
Devon Abt, Annliz Macharia, Michele R Hacker, Rasha Baig, Katharine McKinley Esselen, Jennifer Ducie

International Journal of Gynecologic Cancer Sep 2022, 32 (9) 1091-1097; DOI: 10.1136/ijgc-2022-003521
Adjuvant chemotherapy for stage I high-intermediate risk endometrial carcinoma with lymph-vascular invasion
Dimitrios Nasioudis, Jinhee Oh, Emily M Ko, Ashley F Haggerty, Lori Cory, Robert L Giuntoli, Sarah H Kim, Mark A Morgan, Nawar A Latif

International Journal of Gynecologic Cancer Sep 2022, 32 (9) 1129-1134; DOI: 10.1136/ijgc-2022-003496
Demographic shifts associated with implementation of evidence-based guidelines for ovarian conservation in patients with endometrioid endometrial cancer
Beryl L Manning-Geist, Eric Rios-Doria, Emeline M Aviki, Qin Zhou, Alexia Iasonos, Nadeem R Abu-Rustum, Carol L Brown, Jennifer J Mueller

International Journal of Gynecologic Cancer Sep 2022, 32 (9) 1141-1146; DOI: 10.1136/ijgc-2022-003661
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation
Carmen Garcia-Duran, Francisco Grau, Guillermo Villacampa, Ana Oaknin

International Journal of Gynecologic Cancer Sep 2022, 32 (9) 1196-1200; DOI: 10.1136/ijgc-2022-003370
Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series
Tiffany Y Sia, Beryl Manning-Geist, Sushmita Gordhandas, Rajmohan Murali, Antonio Marra, Ying L Liu, Claire F Friedman, Travis J Hollmann, Oliver Zivanovic, Dennis S Chi, Britta Weigelt, Jason A Konner, Dmitriy Zamarin

International Journal of Gynecologic Cancer Aug 2022, 32 (8) 1017-1024; DOI: 10.1136/ijgc-2022-003430
Safety and efficacy of an outpatient 12-step desensitization protocol for antineoplastic agents
Idil Eroglu, Olga T Filippova, Maria Kirrane, Mary Orpen, Vianca Almonte, Rachel Thomas, Melissa Lee-Teh, Richard Tizon, Nancy Sklarin, Roisin O’Cearbhaill

International Journal of Gynecologic Cancer Aug 2022, 32 (8) 1056-1062; DOI: 10.1136/ijgc-2022-003466

Main menu

Editor's choice

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Editor's choice

Pages